Evidence map›Paper›PMID 33558702›Full record

ArticleCancer gene therapy2022

Knockout of ASPP2 promotes DEN-induced hepatocarcinogenesis via the NF-κB pathway in mice.

Shanshan Wang, Buxin Kou, Mengyin Chai, Yuxue Gao, Xuejun Lin, Ling Yin, Dexi Chen, Xiaoni Liu

Open access · hybridAbstract read
In one paragraph

Article in Cancer gene therapy, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.4field-weighted citation impact, top 36% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Shanshan WangBeijing Institute of Hepatology, Beijing Youan Hospital, Capital Medical University, Beijing, China.
Buxin KouBeijing Institute of Hepatology, Beijing Youan Hospital, Capital Medical University, Beijing, China.
Mengyin ChaiBeijing Institute of Hepatology, Beijing Youan Hospital, Capital Medical University, Beijing, China.
Yuxue GaoBeijing Institute of Hepatology, Beijing Youan Hospital, Capital Medical University, Beijing, China.
Xuejun LinBeijing Institute of Hepatology, Beijing Youan Hospital, Capital Medical University, Beijing, China.
Ling YinBeijing Institute of Hepatology, Beijing Youan Hospital, Capital Medical University, Beijing, China.
Dexi ChenBeijing Institute of Hepatology, Beijing Youan Hospital, Capital Medical University, Beijing, China. dexichen@ccmu.edu.cn.
Xiaoni LiuBeijing Institute of Hepatology, Beijing Youan Hospital, Capital Medical University, Beijing, China. liuxiaoni888@ccmu.edu.cn.ORCID http://orcid.org/0000-0002-8547-3290
Capital Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Apoptosis-stimulating protein p53 2 (ASPP2) is a member of the p53-binding protein family, which is closely related to tumor development. However, the precise mechanism of ASPP2 in liver inflammation and tumorigenesis remains largely unclear. We aimed to characterize the mechanistic significance and clinical implication of ASPP2 in hepatitis and hepatocellular carcinoma (HCC). In this study, ASPP2 knockout (APKO) mice were generated to confirm the role of ASPP2 in the development of hepatitis and HCC. Liver tissues from mice were analyzed by immunohistochemistry, Western blotting, proteomic analysis, ChIP-Seq, and qRT-PCR to evaluate the role of ASPP2 in DEN-induced hepatitis and HCC. We found that APKO promoted the formation of hepatitis/hepatocarcinoma and the increased expression of proinflammatory factors. The proteomics and Western blotting results showed that APKO activated the NF-κB signaling pathway. Further, ChIP-Seq results revealed that NF-κB target genes were dramatically increased in APKO mice. In contrast, blockade of the NF-κB pathway by QNZ reduced the expression of proinflammatory factors and the susceptibility of APKO mice to DEN-induced hepatocarcinogenesis. These results suggested that the absence of ASPP2 activates the NF-κB pathway to promote the occurrence of DEN-induced hepatocarcinogenesis, indicating that ASPP2 may be a potential target for the treatment of hepatocarcinoma.

Indexed as

Carcinoma, HepatocellularLiver NeoplasmsTumor Suppressor ProteinsAnimalsCarcinogenesisHumansMiceMice, KnockoutNF-kappa BProteomicsNF-kappa BTrp53bp2 protein, mouseTumor Suppressor Proteins

Identifiers

PMID33558702
PMCPMC8850195
OpenAlexW3126232004

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.